Effect of Chinese Herbs for Activating Blood Circulation,Removing Stasis and Supplementing Qi on the Circulating Endothelial Cells in Patients with Unstable Angina Pectoris

Objective: To observe the effect and clinical significance of circulating endothelial cells (CEC) in the pathogenesis of coronary heart disease with unstable angina pectoris (CHD-UAP), and to explore the protective effect of Chinese herbs for activating blood circulation, removing stasis and supplementing Qi (CH) on CHD-UAP patient's CEC. Methods: Sixty patients with diagnosis of CHD-UAP confirmed and differentiated to be Qi-deficiency and blood stasis by TCM were randomly divided into two groups and treated, on the basis of Western drug-therapy, with Tongxinluo capsule (通心络胶囊, TXL) and Huoxue Tongmai capsule (活血通脉胶囊, HXTM) respectively by way of oral taking three times a day, 3 capsules every time, with 1 month as one therapeutic course. The number of CEC in patients' blood circulation was counted before and after treatment. Besides, the number of CEC in 30 healthy persons was also counted for control. Results: The number of CEC in CHD-UAP patients was significantly higher than that in the healthy persons (P<0.01). After the patients were treated with CH, either TXL or HXTM, it significantly decreased (P<0.01)with insignificant difference between the two treated groups. Conclusion: CEC in CHD-UAP patients is severely damaged and endothelial function in disorder, Chinese herbs have protective effect on patients' CEC.

Treatment of Hypertensive Cerebral Hemorrhage by Activating Blood Circulation to Remove Stasis

The treatment of hy-pertensive cerebral hemorrhage(HCH)by activatingblood circulation to removestasis(ABCRS)is a newtherapeutic approach,which is initiated by clinical specialists of TCM andintegrative Chinese andwestern medicine.Al-though it is not a flawless

Efficacy and safety of activating blood circulation and removing blood stasis of Traditional Chinese Medicine for managing renal fibrosis in patients with chronic kidney disease:a systematic review and Meta-analysis

OBJECTIVE:To evaluate the efficacy and safety of activating blood circulation and removing blood stasis in terms of Traditional Chinese Medicine(TCM) for managing renal fibrosis(RF) in patients with chronic kidney disease(CKD).METHODS:We searched randomized controlled trials(RCTs) from eight databases.RESULTS:Sixteen eligible studies with 1,356 participants were included in this study.Compared to treatment with Western Medicine(WM) alone,the combined treatment with activating blood circulation and removing blood stasis in terms of TCM(ARTCM) and WM to manage RF in patients with CKD significantly ameliorated type Ⅳ collagen(C-Ⅳ)(SMD:-2.17,95% CI:3.01 to-1.34),type Ⅲ procollagen(PC-Ⅲ)(SMD:-1.08,95% CI:-1.64 to-0.53),laminin(LN)(SMD:-1.28,95% CI:-1.65 to-0.90),transforming growth factor β 1(TGF-β1)(SMD:-0.65,95% CI:-1.18 to-0.12),serum creatinine(Scr)(SMD:-1.36,95% CI:-1.85 to-0.87),blood urea nitrogen(BUN)(MD:-1.51,95% CI:-2.59 to-0.43),and 24 h urine protein(24h Upro)(SMD:-1.23;95% CI:-1.96 to-0.50).The level of hyaluronic acid(HA) was similar in both types of treatment(SMD:-0.74,95% CI:-1.91 to 0.44).The subgroup analysis showed that the duration of 8 weeks might affect the concentration of C-Ⅳ,PC-Ⅲ,and LN(P < 0.05).The effectiveness of the longer duration to C-Ⅳ,PC-Ⅲ,and LN was not certain.However,the result should be interpreted in care.The safety of the treatment using ARTCM and WM could not be evaluated because a few studies had reported adverse effects.The results of the Meta-analysis were not stable enough.There was publication bias for the reports on Scr(P = 0.001),C-Ⅳ(P = 0.001),PC-Ⅲ(P = 0.026),and LN(P = 0.030) and no publication bias for the reports on BUN(P = 0.293).The quality of evidence varied from low to very low.CONCLUSIONS:The combined treatment using ARTCM and WM to manage RF in patients with CKD has some advantages over treatment with WM alone.High-quality RCTs need to be conducted for the strong support.

Exploration of the Effect and Mechanism of Activating Blood Circulation and Stasis-Removing Therapy on Tumor Metastasis

Metastasis is one of the specificities of late stage tumor and also a lethal factor often encountered. The study of tumor metastasis has important meaning for prolonging patients＇ survival and elevating their quality of life, but no really ideal prevention and treatment method has been found so far. Recent researches showed that tumor metastasis is correlated with platelet aggregation and blood hyperviscosity manner. Therefore, the early application of surgery, radiotherapy, chemotherapy and biological therapies, in combination with Chinese medicine therapy for activating blood circulation and removing stasis （ABCRS） may be, after all, an effective approach. ABCRS therapy is an important therapy of Chinese medicine, which, composed of several methods like smoothening blood flow in vessels, promoting blood circulation and dispersing stagnant blood, could influence tumor metastasis to different extents, and could coordinate with some other Chinese medicine therapeutic methods like supplementing qi, promoting qi, clearing heat, removing toxic substances, warming meridian, dispelling wind, eliminating dampness, nourishing yin, dissolving sputum, relieving stagnancy, emptying viscerals, etc. The effect and acting mechanism of ABCRS on tumor metastasis is summarized in this paper and its bi-directional regulatory effects discussed as well.

Activating Blood Circulation to Remove Stasis Treatment of Hypertensive Intracerebral Hemorrhage:A Multi-Center Prospective Randomized Open-Label Blinded-Endpoint Trial

Objective： To investigate the efficacy and safety of the Chinese herbal therapeutic regimen of activating blood circulation （TRABC） in treatment of hypertensive intracerebral hemorrhage （HICH）. Methods： This was a multi-center prospective randomized open-label blinded-endpoint （PROBE） trial with HICH admitted to 12 hospitals. Totally 240 participants were randomized to the treatment group treated with TRABC in addition to conventional Western treatment or the control group with conventional Western treatment equally for 3 months. Primary outcome was degree of disability as measured by modified Rankin Scale （mRS）. Secondary outcomes were the absorption of hematoma and edema, National Institutes of Health Stroke Scale （NIHSS） scores and patient-reported outcome measures for stroke and Barthel activities of daily living index. Adverse events and mortality were also recorded. Results： After 3 months of treatment, the rate of mRS 0-1 and mRS 0-2 in the treatment group was 72.5% and 80.4%, respectively, and in the control group 48.1% and 63.9%, respectively, with a significant difference between groups （P〈0.01）. Hematoma volume decreased significantly at day 7 of treatment in the treatment group than the control group （P=0.038）. Average Barthel scores in the treatment group after treatment was 89.11 ＋ 19.93, and in the control group 82.18 ＋ 24.02 （P=0.003）. NIHSS scores of the two groups after treatment decreased significantly compared with before treatment （P=0.001）. Patient-reported outcomes in the treatment group were lower than the control group at day 21 and 3 months of treatment （P〈0.05）. There were 4 deaths, 2 in each group, and 11 adverse events, 6 in the treatment group and 5 in the control group. Conclusion： The integrative therapy combined TRABC with conventional Western treatment for HICH could promote hematoma absorption thus minimize neurologic impairment, without increasing intracerebral hematoma expansion and re-bleeding.

Study on the Therapeutic Mechanism of the Active Principle of the Chinese Drug Paeoniae Radix 801 through Affinity Biosensors IAsys Plus Quartz Crystal Microbalance

Objective: To study the targeted point and mechanism of the function of the blood-activating and stasis-removing Chinese drugs, Paeoniae Radix 801(PR801) in its cardiovascular protective effects and its specific binding with endothelin 1(ET-1) as well as the dynamics of the two's interactive function by means of using affinity biosensors: IAsys Plus and quartz crystal microbalance (IAQCM). Methods: ET-1 was immobilized on the surfaces of IAQCM by using the new surface modification methods. The PR801 in the solution was detected by modified substrates and the specific binding between PR801 and ET-1 was studied. Results: The curves went up or down after adding PR801.There is specific binding between PR801 and ET-1. The bound mass were 0.458 ng/mm 2 and 133.54 ng/cm 2, respectively. There exists relatively good stability with these two methods. Conclusion: The affinity biosensors: IAQCM can be used to study the interaction mechanism between PR801 and ET-1, providing a new way to study the interaction mechanism of TCM. PR801 can bind ET-1 specifically in the experiments. Therefore, ET-1 is another target that PR801 can bind specifically besides thromboxane A 2.

活血化瘀涂搽药治疗冠脉介入穿刺并发症临床观察

目的观察活血化瘀涂搽药剂外敷治疗冠脉介入穿刺并发症的疗效。方法选取2021年1月1日—2022年12月31日在江西中医药大学附属医院行冠脉介入治疗后伴桡动脉穿刺点并发症的患者100例,随机分为试验组和对照组,各50例。对照组采用50%硫酸镁湿敷,试验组采用活血化瘀涂搽药剂湿敷,均连续治疗7 d,比较2组穿刺部位淤青面积变化、穿刺部位肿胀程度、穿刺部位疼痛程度及临床有效率。结果2组患者淤青面积、肿胀程度及疼痛评分均较治疗前降低(P<0.05),且试验组均低于对照组(P<0.05),试验组总有效率高于对照组(P<0.05)。结论活血化瘀涂搽药剂外敷相对于硫酸镁外敷更能有效减少冠脉介入穿刺并发症患者的淤青面积、肿胀程度及疼痛评分,提高临床有效率,疗效好,值得临床推广应用。

Effect on platelet aggregation activity: extracts from 31 Traditional Chinese Medicines with the property of activating blood and resolving stasis

OBJECTIVE: To evaluate the anti-platelet aggregation effects of extracts from 31 Traditional Chinese Medicines(TCM) with the property of activating blood and resolving stasis in terms of TCM theory.METHODS: The 31 TCMs extracts were prepared using water, 90% ethanol and ethyl acetate., and the effects on anti-platelet aggregation were tested on a platelet aggregation analyzer in vitro with adenosine 5'-diphosphate, bovine thrombin and arachi-donic acid(AA) as aggregation inducers, respectively. Aspirin was the positive control.RESULTS: Lots of the tested TCMs had inhibitory effects with concentration-dependent manner on platelet aggregations induced by various agonists.Especially, some of the TCMs such as Chuanxiong(Rhizoma Chuanxiong), Yanhusuo(Rhizoma Corydalis Yanhusuo) and Danshen(Radix Salviae Miltiorrhizae) showed good anti-platelet aggregation effect similar or higher than that in positive control group.CONCLUSION: The study provided scientific references that several TCMs such as Chuanxiong(Rhizoma Chuanxiong), Yanhusuo(Rhizoma Corydalis Yanhusuo) and Danshen(Radix Salviae Miltiorrhizae),possess the property of anti-platelet aggregation.

蔡平平基于八纲辨证治疗绒毛膜下血肿经验采撷

介绍蔡平平教授基于八纲辨证治疗绒毛膜下血肿(SCH)的临床经验。在SCH的诊疗中,以八纲辨证为指导,强调阴阳辨证,灵活使用活血化瘀法;以“活血不留瘀、不动血、不动胎、不碍胎”为原则,提出“急则止血,缓则消瘀,澄源安胎为本”的治疗方法,同时宏观和微观相结合,重视脉诊。

费伯雄学术思想浅论骨肿瘤证治思路

本文在费伯雄的“醇正和缓,平淡和调”思想基础上的创新与发挥,阐述了中医对骨肿瘤的认识,将“固本清源”、“脾肾同治”“、费氏活血化瘀法”等应用于骨肿瘤辨证体系,对于“龙火汤”“立极汤”“后辛汤”“新定拯阴理劳汤”等进行创新应用,使其内涵与意义更符合现代中医药辨治肿瘤病的特点。在临床上灵活地按照肿瘤病发生发展的不同阶段分成了四期演变,并从病因、病机与治则方面辨治骨肿瘤发热以及骨肿瘤相关性失眠,在费伯雄学术思想指导下为临床骨肿瘤的诊治提供新思路。

活血化瘀穴位贴敷联合延伸护理对人工流产术后康复水平及生活质量的影响

目的:探讨活血化瘀穴位贴敷联合延伸护理对人工流产术后康复水平及生活质量的影响。方法:选取本院2022年1月至2022年12月收治的80例人工流产患者作为研究对象,应用抽签法将其分为观察组与对照组,各组均为40例。对照组实施常规护理干预,观察组在对照组基础上增加活血化痧穴位贴敷联合延伸护理。对比两组患者术后康复水平,并在护理前与护理1个月后对比两组患者疾病知识和负面情绪情况和评估两组患者生活质量。结果:观察组患者疼痛持续时间、月经复潮时间、阴道出血时间明显低于对照组(P<0.05);护理后两组患者避孕知识、生殖健康知识评分均升高,观察组高于对照组,HAMD,HAMA评分降低,观察组低于对照组(P>0.05);两组患者干预后生活质量相关评分均升高,且观察组高于对照组(P<0.05)。结论:活血化瘀穴位贴敷联合延伸护理可促进患者术后康复水平提升,减少患者疼痛、月经复潮和阴道出血时间另外能够进一步提升患者疾病健康知识,改善负面情绪,提升患者生活质量。

活血化瘀中药联合富血小板血浆改善激素性股骨头坏死的作用机制

背景:目前发现活血化瘀中药、富血小板血浆技术都能够修复受损血管,促进血管再生,重建股骨头内血运,恢复正常血供,进一步促进成骨作用,在早期干预激素性股骨头坏死方面均表现出一定的优势,可更加深入了解活血化瘀中药及富血小板血浆技术改善激素性股骨头坏死的作用机制,为今后治疗提供新思路。目的:根据国内外相关文献,综述活血化瘀中药联合富血小板血浆技术改善激素性股骨头坏死作用机制的研究进展。方法:检索PubMed、Web of Science、Metstr、中国知网及万方数据库收录的相关文献。以“中药、信号通路、激素性股骨头坏死、血管内皮生长因子、富血小板血浆”及“traditional Chinese medicine、signal pathways、steroid induced necrosis of femoral head、vascular endothelial growth factor、platelet rich plasma”分别作为中、英文检索词,检索文献时限为2000年1月至2022年7月,最终纳入相关文献75篇。结果与结论:活血化瘀中药及富血小板血浆技术在干预早期激素性股骨头坏死方面均表现出一定的优势。对于中医药而言,无论是活血化瘀单体药还是复方药都可以有效缓解激素性股骨头坏死疾病进一步发展,具体作用机制如下:①活血化瘀中药有显著抗凝作用,可以拮抗激素药物造成的血液异常(高凝)状态,进一步恢复股骨头内的正常血供;②活血化瘀中药可修复受损的血管内皮,通过激活血管内皮生长因子,使血管再生,重塑股骨头内血运;③活血化瘀中药祛瘀效果明显,可减少骨髓腔内的脂肪细胞堆积,缓解股骨头内压力;④活血化瘀中药可调控相关信号通路,维持骨代谢,促进成骨细胞、破骨细胞分化平衡,有效减轻激素性股骨头坏死。此外,富血小板血浆中含有大量高浓度细胞生长因子,对成骨作用及血管再生均起到正向作用,同时也可改善血液异常状态。活血化瘀中药联合富血小板血浆技术可发挥二者自身生物作用,干预效果更加显著。

柳国斌教授从“寒凝血瘀”论治血栓闭塞性脉管炎的经验

本文对柳国斌教授治疗血栓闭塞性脉管炎的学术思想进行总结。柳教授提出阳虚寒凝是血栓闭塞性脉管炎的始动病机,而后形成瘀血、脉络闭阻等病理环节,故将本病的病机概括为“寒凝经脉,瘀血阻络”,其提出以“温经散寒,活血通络”为治疗法则,遣方用药注重扶阳,认为机体的阳气充足后,气血得以运行顺畅,瘀血等病理因素随之消散。柳教授强调只有抓住病机才能抓住治疗的关键,在复杂的疾病中找出矛盾所在,才能取得良效。现将柳教授临证经验总结如下,并附验案1则,为治疗血栓闭塞性脉管炎提供思路。

基于隐结构模型结合关联规则探讨冠脉微血管疾病中医“症-证-药”规律

目的系统挖掘冠状动脉微血管疾病(Coronary microvascular disease,CMVD)中医常见症状、证候要素、临床辨证分型及用药规律,为量化CMVD临床辨证标准、规范中医临床证候诊断及疗效评价、指导临床用药提供参考依据。方法分别检索中国知网(CNKI)、万方数据库(Wanfang)、维普中文期刊(VIP)、中国生物医学文献服务系统(SinoMed)自建库至2023年5月16日有关中医药治疗CMVD的相关文献。提取纳入文献相关信息建立数据库并对症状、证素、证型、中药进行频数统计,分别采用Latern 5.0与Rstudio软件构建隐结构模型进行综合聚类与关联规则分析,探讨中医药治疗CMVD的症状特点、证素分布、常见证型及用药规律。结果共纳入107篇文献,涉及证型36个,证素17个,症状121个,中药143种,推测出CMVD的主要证候要素为血瘀,其次为气虚、气滞、痰浊、阴虚和阳虚;主要证型为气虚血瘀证,其次为心血瘀阻证、气滞血瘀证、痰瘀互结证、气阴两虚证等;用药以川芎、丹参、当归、黄芪为主;按功效分类主要为活血化瘀药、补虚药、理气药。结论CMVD病位在心,与肝、肾相关,属本虚标实之证,血瘀贯穿本病发展的始终;治疗以活血化瘀、通络止痛为主,并结合辨证选用补中益气、疏肝理气、祛痰散结等治法。

吴伟基于“瘀毒致悸”辨治房颤思路探讨

吴伟教授在辨治房颤过程中,创新性地提出“心-血-脉三位一体论”与“瘀毒致悸”论。认为房颤由瘀毒所致,其病位在心-血-脉,核心病机为“气滞血瘀毒成”。治法当紧扣病机,提倡“从瘀论治,兼以解毒,缓消其毒”,且认为理气活血化瘀便是解毒。方拟桃仁红花煎加减,主要组成药物有桃仁、红花、川芎、延胡索、生地黄、赤芍、丹参、大枣、葛根、甘松、牡蛎、茯苓、玉竹等,并根据岭南之气候与房颤多影响情志之特点,去方中辛烈之品,而加特色解毒药对葛根-甘松以辨病而治。吴伟教授治疗房颤还常配合沐足、针灸、导引等中医外治法和保健法,全面调理,缓消其毒,以复其元。吴伟教授治疗房颤采用中医药精准干预,综合调理,可达到促进症状消失及恢复窦性心律、改善体质等目的,其辨治思路可为房颤的中医药治疗提供参考。

中药相关性肝损伤潜在可疑中药识别及临床特征分析

目的探讨通过医院大数据平台发现药物性肝损伤风险信号的方式,筛选出可能会诱发肝损伤的相关中药,分析中药相关性肝损伤的易感因素。方法收集2019年6月1日至2023年6月1日数据,对药物性肝损伤的诊断先确认存在肝损伤,其次除外其他肝病,再通过Roussel-Uclaf因果关系评估法(RUCAM)对药物与肝损伤的因果关系进行量化评估;再剔除合并用药中致药物性肝损伤使用化药(主要是A类及B类的药物)的住院患者,发现并整理出可疑中药品种,分为可能、有可能、不太可能、不可能4类。结果共收集肝功能异常患者2056例,筛选出可能中药相关性肝损伤患者142例,其中可能及有可能药物种类主要包括解表药、清热解毒药、活血化瘀药、祛风湿药等。结论可疑中药种类涉及范围较广,药物性肝损伤的发生可能与人体机体状态、药物本身有关,发生药物性肝损伤的机制可能与免疫炎症促进相关。

基于虚实辨证的大肠癌血瘀证中医药治疗和作用机制研究进展

血瘀证是大肠癌患者常见的中医证型,血瘀贯穿于大肠癌发生发展的各个阶段,活血化瘀法是临床治疗大肠癌的常用方法。从因虚致瘀、由实成瘀两个角度探讨大肠癌血瘀证的病因病机和临床治疗,并从增殖凋亡、血管新生、细胞自噬、侵袭转移、免疫调节、微循环障碍等方面综述活血化瘀中药治疗大肠癌血瘀证的作用机制,以期为临床使用活血化瘀法治疗大肠癌提供依据。

司徒仪辨治子宫内膜异位症规律的数据挖掘

【目的】基于个性化知识图谱分析和数据挖掘技术,探讨广东省名中医司徒仪教授辨治子宫内膜异位症(endometriosis,EMs)规律,为EMs的中医诊疗提供参考。【方法】基于EMs诊治的文献研究基础,采用人机结合方法建立名医理法方药本体知识树;采集司徒仪教授于2013年至2019年在广东省中医院门诊诊治的EMs患者的病历,对采集的病案信息进行规范化处理后,形成知识集,构建EMs的中医药诊疗知识图谱,分析疾病特征与用药规律。【结果】EMs患者的核心症状群为痛经、慢性盆腔痛、不孕,证候以血瘀为核心,气滞、肾虚、气虚为主要病机。频繁项集分析得到的核心药物组合有“延胡索-香附-白芍”“枸杞子-桑寄生-茯苓-山药”“枳壳-益母草”等。基于知识元聚类和神经网络算法而构建的EMs词云图显示,丹参-赤芍、延胡索-郁金、桂枝-牡丹皮-赤芍-茯苓、丹参-赤芍-三棱-莪术、川芎-延胡索、桑寄生-菟丝子等为司徒仪教授治疗EMs的常用药物组合。有关中药、症状、证型之间的层次聚类分析和关联网络构建结果显示,证型、症状、用药间存在复杂的内在联系。【结论】司徒仪教授治疗EMs以活血化瘀、补肾为主要治疗方法,同时顺应月经周期,攻补兼施。基于语义网络的知识图谱分析与数据挖掘有助于将司徒仪教授的临床诊治经验的隐性知识显性化,可为EMs的中医辨治提供借鉴。

芎芍胶囊治疗冠心病心绞痛临床疗效及安全性的系统评价

目的:系统评价芎芍胶囊治疗冠心病心绞痛的临床效果及安全性。方法:计算机检索Web of SCI、PubMed、EMbase、the Cochrane Library、万方数据资源系统(WanFang Database)、维普中文科技期刊全文数据库(VIP)、中国知网(CNKI)、中国生物医学文献服务系统(SinoMed)等数据库,纳入芎芍胶囊对比单独使用常规西药或血府逐瘀胶囊干预冠心病心绞痛的随机对照试验研究(RCT)。由2位评价者独立筛选提取文献资料、评定偏倚风险,使用RevMan 5.3进行Meta分析。结果:纳入12项研究,涉及1309例病人。Meta分析结果显示,试验组在提高临床总有效率[RR=1.17,95%CI(1.11,1.23),P<0.00001]、提高心电图疗效[RR=1.22,95%CI(1.09,1.36),P=0.0003]、降低三酰甘油(TG)[MD=-0.19,95%CI(-0.35,-0.04),P=0.02]、升高高密度脂蛋白胆固醇(HDL-C)[MD=0.13,95%CI(0.07,0.19),P<0.0001]方面均优于对照组,而两组在减低总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及不良反应发生率方面比较差异无统计学意义(P>0.05)。结论:现有证据表明,芎芍胶囊治疗冠心病心绞痛的临床效果明确,安全性较好。

A PROSPECTIVE STUDY TO EVALUATE THE SAFETY AND EFFICACY USING REMOVING BLOOD STASIS HERBALS FOR PATIENTS WITH INTRACRANIAL HEMORRHAGE OF HYPERACUTE STAGE AND RELATIVE FACTORS OF HEMATOMA ENLARGEMENT(A MULTICENTER PROSPECTIVE RANDOMIZED DOUBLE-BLIND PLACEBO

The aim was to investigate whether using a removing blood stasis method in hyperacute intracranial hemorrhage stage can lead to hematoma enlargement and its clinical efficacy.A multicenter retrospective randomized double-blind placebo-controlled clinical study.We recruited patients aged 18 years or older and presenting at less than 6 h from symptom onset in 8 research centers.All the patients